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Introduction: Ciclosporin A (CsA) is considered to be a major
component in the prophylaxis and treatment of acute and chronic
graft-versus-host-disease (GvHD) after allogeneic hematopoietic
stem cell transplantation (HSCT). However, impairment of renal
function and CNS toxicity may complicate or even inhibit the use
of calcineurin-inhibitors (CNI). Here, we report the use of siroli-
mus/MMF in two children with acute/chronic GvHD and signif-
icant CNI-associated toxicities. Case Reports: Two patients, a
14-year-old boy and a 4-year-old girl, were transplanted for ALL
and AML, respectively. They received bone marrow from their
HLA-identical siblings and GvHD-prophylaxis with MTX and
CsA. Patient 1, the boy, stayed on CsA until day 27, when he
complained of dizziness and disorientation. The cranial MRI ﬁnd-
ings were consistent with CsA-induced neurotoxicity. He was set
on tacrolimus until day 95, when he presented with cerebral
seizures and somnolence. In the absence of acute GvHD and the
presumption of tacrolimus-induced neurotoxicity, the drug was
discontinued. One week later, the presence of GvHD of skin and
gut could be conﬁrmed by biopsy. During his previous anti-leuke-
mic therapy, the patient had suffered from severe side effects of
high-dosed steroids. So, in an attempt to minimize the use of
steroids, he was set on sirolimus/MMF with a short course of
prednisone. He rapidly responded to this regimen. Steroids were
discontinued after a few days. The boy stayed on sirolimus/MMF
for four months without evidence of recurrent GvHD. Patient 2
was switched early to tacrolimus because of a status of stupor
and suspected CsA-neurotoxicity. She developed stage 4 gut
GvHD on day 45, responsive to a highly immunosuppressive
therapy including inﬂiximab. Eleven months post-transplant,
while on tacrolimus, she had increasing renal insufﬁciency with
a creatinine clearance of 30 ml/min and a urea of 120 mg/dl. She
was set on sirolimus/MMF; in the transition phase to that
regimen she had another, steroid-responsive ﬂare of her gut
GvHD. Eighteen months post-transplant, the girl’s GvHD is
under good control with sirolimus and low dose steroids. Renal
function tests are within normal limits. Conclusion: In HSCT
recipients with severe calcineurin-inhibitor neurotoxicity or im-
paired renal function, the use of sirolimus/MMF should be
considered when continuation of immunosuppressive therapy is
mandatory for control of GvHD.
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Syngeneic graft-versus-host disease (SGVHD), characterized
by a TH1 cytokine response, and intestinal inﬂammation devel-
ops following lethal irradiation, reconstitution with syngeneic
bone marrow, and treatment for 21 days with cyclosporine A
(CsA). It has generally been assumed that the T cell responses
associated with SGVHD resulted from the reconstitution of
irradiated recipients with donor bone marrow. However, to
determine the origin of the effector cells that mediate SGVHD,
syngeneic bone marrow from normal immunocompetent mice
or immunodeﬁcient mice were transferred into lethally irradi-
ated recipients. Following CsA treatment, mice within both
groups developed inﬂammation characteristic of SGVHD in the
colon and liver. Furthermore, increases in the expression of TH1
cytokines, levels of colonic CD4 T cells and expression of
activated peripheral CD4 T cells were comparable regardless
of whether CsA-treated animals received T cell sufﬁcient (nor-
mal) or T cell deﬁcient (SCID) bone marrow. These results
demonstrate that in the absence of donor T cells, recipient T
cells can expand and mediate the induction of CsA-induced
SGVHD.
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The effective therapy for nasal natural-killer (NK) cell lym-
phoma is not established, and there is no report that the graft-
versus-lymphoma effect (GVLE) against the nasal NK cell lym-
phoma was deﬁnitively conﬁrmed. We report a patient with nasal
NK cell lymphoma who relapsed after allogeneic transplant and
developed fatal tumor lysis reaction during the attempt of inducing
graft-versus-host disease (GVHD). The patient was 53-year-old
woman suffering from a rapidly progressing nasal NK cell lym-
phoma metastasis to the skin, adrenal grand and abdominal lymph
nodes. She received three courses of combination chemotherapy
followed by high-dose therapy with a rescue of autologous haema-
topoietic stem cell transplant (HSCT). Following attainment of
partial remission, she underwent allogeneic HSCT from an HLA-
matched sibling prepared with reduced-intensity regimen and at-
tained complete remission. In the subsequent course, she had no
acute GVHD, but had extensive chronic GVHD mainly on skin,
requiring some immunosuppressions. Seven months after alloge-
neic HSCT, she developed fever and pancytopenia. A general
search revealed bone marrow relapse without any other lesion.
Immunosuppressions were tapered with expecting GVLE. Two
weeks after the withdrawal, she suddenly developed tachypnea.
Emergent laboratory data revealed signiﬁcant hyperkalemia, hy-
peruricemia, metabolic acidosis. We also found the marked de-
crease of tumor cells in a bone marrow aspiration specimen. After
the tumor lysis reaction, the patient developed severe renal and
hepatic dysfunction, causing her death despite intensive care. This
is the ﬁrst case report that deﬁnitely conﬁrmed a GVLE against
NKCL.
HISTOCOMPATIBILITY/ALTERNATIVE
STEM CELL SOURCES
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FACTORS PREDICT HEMATOPOIETIC RECOVERY IN PATIENTS WITH
FANCONI ANEMIA (FA) AFTER ALTERNATE DONOR (AD) HEMATOPOI-
ETIC STEM CELL TRANSPLANTATION (HSCT)
Al-Sweedan, S.A., Wagner, J.E., Tan, Y., DeFor, T.E.,
MacMillan, M.L. University of Minnesota, Minneapolis, MN.
As engraftment has been a signiﬁcant barrier to successful AD
HSCT (deﬁned as bone marrow [BM] or umbilical cord blood
[UCB] from a donor other than an HLA matched sibling), we
attempted to identify risk factors predictive of hematopoietic
recovery in this setting. Therefore, we evaluated engraftment in
83 FA patients aged 0.8–48.5 years (median 11.8) who under-
went T cell depleted BMT [(TCD, n  31), no TCD BMT (n 
37) or UCBT (n  15)] at the University of Minnesota from
1990 to 2004. 55% had aplastic anemia and 34% had myelodys-
plastic syndrome/acute myeloid leukemia at time of HSCT;
34% were CMV seropositive; 60% had HLA matched donors.
All received 40 mg/kg cyclophosphamide and 450 or 600 cGy
total body irradiation with 65% also treated with ﬂudarabine
(FLU) 140 mg/m2. BM Grafts contained 0.82–9.32  106CD34
cells/kg and 0.66–2.57  103 CD3 cells/kg and UCB grafts
contained 0.01– 0.91  106CD34 cells/kg and 0.03–0.24  103
CD3 cells/Kg. In univariate analysis, factors associated with
signiﬁcantly improved incidence of neutrophil recovery(	500/
uL) were no TCD-BM (94%) and TCD-BM in presence of
FLU (91%) compared to 83% and 68% in recipients of UCB
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